Efficacy and Safety Study of Nidadd in the Management of Hyperlipidemia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-10-31

Study Completion Date

2005-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To assess the efficacy and safety of Nidadd (extended-release niacin) in patients with hyperlipidemia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Niacin on Transport of HDL and Relationship to Atherogenic Lipoproteins and Lipolysis

NCT01250990

Dyslipidemias

COMPLETED NA

Comparison of Fenofibrate and Niacin in Patients With Hypertriglyceridemia and Low High-Density Lipoprotein (HDL)-Cholesterol

NCT01122355

Hypertriglyceridemia With Low HDL-cholesterol

COMPLETED PHASE4

Efficacy of Nicotine Acid on Dyslipidaemia in Patients With Metabolic Syndrome

NCT00659321

Metabolic Syndrome Dyslipidaemia

COMPLETED PHASE3

Efficacy of Ethyl Icosapentate in Patients With Severe Hypertriglyceridemia

NCT04239950

Hypertriglyceridemia

COMPLETED PHASE3

the Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects in Adult Subjects With Elevated LDL-C

NCT06132360

To Reduce the LDL-C Level in Hypercholesteremia Patients

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a randomized, double-blind, placebo-controlled, and multicenter study. A total of at least 50 patients will be recruited to achieve 40 evaluable patients required to assess the safety and efficacy of escalating doses of extended-release Nidadd in hyperlipidemic patients.

1. The trial begins with measurement of baseline lipid levels. Fasting blood samples will be collected at screening and each treatment visit (except visit 3) for lipid analysis and safety monitoring. Chemistry laboratory tests and hematological testing are performed periodically. Patient's diet education will be given by dieticians or appropriately trained counselors at visit 1 and 2.
2. Patients who are taking any lipid-modifying drugs will be required to go through a 4-week washout / diet-controlled period prior to randomization (visit 2).
3. Treatment duration is 16 weeks in total: Patients randomized to treatment with Nidadd will receive 500 mg for the first 8 weeks of the medication period. For another 8 weeks, the dose is then increased to 1000 mg and is maintained to the end of the study. The patients in control group will take placebo in a same fashion as that of Nidadd group throughout entire 16 weeks.
4. The primary measure of efficacy is the change from baseline in serum HDL-c level. Secondary measures of efficacy are changes from baseline in serum total cholesterol, LDL-c, and triglycerides.
5. Safety and tolerability will be evaluated from adverse events, number of patients who prematurely discontinue the trial because of adverse events, and laboratory measures.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hyperlipidemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nidadd

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male and female subjects between the ages of 20 and 75 years.
2. An at least 4 weeks wash-out / diet-controlled period before study entry is required.
3. HDL cholesterol \< 40 mg/dL for male and \< 50 mg/dL for female; and triglyceride levels ≧ 200 mg/dL.
4. Being mentally competent and able to understand all study requirements and sign the informed consent form.

Exclusion Criteria

1. Total cholesterol ≧ 300 mg/dL; triglyceride levels ≧ 1000 mg/dL.
2. Having FPG level greater than 180 mg/dL after a 4-week washout / diet control period.
3. Type-1 diabetes mellitus; or type-2 diabetes mellitus without stable (fixed dose) medication.
4. Pregnant or lactating women or women of childbearing potential whom are not practicing a reliable form of birth control (either with IUD or with stable usage of oral contraceptives).
5. Concomitant steroid therapy.
6. Received any lipid-modifying agents within the four weeks of wash-out / diet-controlled period.
7. With clinically significant cardiac arrhythmias or other serious cardiac abnormalities; received coronary artery bypass graft or percutaneous transluminal coronary angioplasty within 6 months prior to study entry.
8. Malignant tumor (except for squamous/basal cell skin cancer), or chronic terminal disease (e.g. AIDS, liver cirrhosis, etc.) within past 5 years.
9. With any disorders or conditions which, in the opinion of the investigator will preclude successful compliant participation in the study.
10. Nephrotic syndrome or any other renal dysfunction, serum creatinine \> 2.0 mg/dl; active hepatic dysfunction, SGPT, SGOT, gGT, or alkaline phosphatase value greater than 2 times the upper limit of normal.
11. With pancreatitis, gallbladder disease, or active peptic ulcer disease within 6 months.
12. Active gouty arthritis.
13. Taken any other investigational drug within one month prior to study entry.
14. With known hypersensitivity to niacin.
15. With a history of alcohol and/or drug abuse.

Minimum Eligible Age

20 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No